TD Asset Management
NGNE icon

TD Asset Management’s Neurogene NGNE Stock Holding History

TD Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,800
Closed -$361K – 1250
2024
Q4 		$361K Buy
+15,800
New +$588K ﹤0.01% 1200
2019
Q4 		– Sell
-1,029
Closed -$59K – 1413
2019
Q3 		$59K Buy
+1,029
New +$62.8K ﹤0.01% 1328
2018
Q3 		– Sell
-2,127
Closed -$113K – 1447
2018
Q2 		$113K Sell
2,127
-2,346
-52% -$611K ﹤0.01% 1405
2018
Q1 		$1.26M Buy
4,473
+241
+6% +$66.5K ﹤0.01% 997
2017
Q4 		$995K Hold
4,232
– – ﹤0.01% 1052
2017
Q3 		$1.2M Hold
4,232
– – ﹤0.01% 989
2017
Q2 		$1.19M Hold
4,232
– – ﹤0.01% 1006
2017
Q1 		$1.41M Sell
4,232
-15
-0.4% -$5.27K ﹤0.01% 958
2016
Q4 		$1.4M Buy
4,247
+312
+8% +$83.9K ﹤0.01% 945
2016
Q3 		$1.05M Buy
+3,935
New +$793K ﹤0.01% 998

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

TD Asset Management's NGNE Position: Q1 2025 in Review

TD Asset Management sold out of Neurogene (NGNE) in Q1 2025, closing a stake of 15,800 shares — an estimated $361K sold.

TD Asset Management first reported a position in NGNE in Q3 2016 and held it in 10 quarters. The position peaked at $1.41M in Q1 2017. 85 funds tracked by Wall St. Rank hold NGNE as of Q1 2025.

  • TD Asset Management reported no remaining Neurogene position as of Q1 2025 after selling out during the quarter.
  • TD Asset Management sold 15,800 Neurogene shares in Q1 2025, an estimated $361K.
  • TD Asset Management first reported a position in Neurogene in Q3 2016 and held it in 10 quarters.
  • TD Asset Management's Neurogene position peaked at $1.41M in Q1 2017.
  • 85 funds tracked by Wall St. Rank held Neurogene as of Q1 2025.

Based on TD Asset Management's 13F filing for Q1 2025, filed 7 May 2025.